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The role of molecular arrangement of hydrophobic and hydrophilic groups for designing 
membrane-active molecules remains largely ambiguous. To explore this aspect, herein we report 
a series of membrane-active small molecules by varying the spatial distribution of hydrophobic 
groups. The two terminal amino groups of linear triamines such as diethylene triamine, 
bis(trimethylene)triamine and bis(hexamethylene)triamine were conjugated with cationic amino 
acids bearing variable side chain hydrophobicity (such as diaminobutyric acid, ornithine and 
lysine). The hydrophobicity was also modulated through conjugation of different long chain fatty 
acids with the central secondary amino group of the triamine. Molecules with constant backbone 
hydrophobicity displayed an enhanced antibacterial activity and decreased hemolytic activity 
upon increasing the side chain hydrophobicity of amino acids. On the other hand, increased 
hydrophobicity in the backbone introduced a slight hemolytic activity but a higher increment in 
antibacterial activity resulting in better selective antibacterial compounds. The optimized lead 
compound derived from structure-activity-relationship (SAR) studies was the dodecanoyl 
analogue of lysine series of compounds consisting of bis(hexamethylene)triamine as the 
backbone. This compound was active against various Gram-positive and Gram-negative bacteria 
at a low concentration (MIC ranged between 3.1-6.3 µg/mL) and displayed low toxicity towards 
mammalian cells (HC50 = 890 µg/mL and EC50 against HEK = 85 µg/mL). Additionally, it was 
able to kill metabolically inactive bacterial cells and eradicate preformed biofilms of MRSA. 
This compound showed excellent activity in a mouse model of skin-infection with reduction of 
~4 log MRSA burden at 40 mg/kg dose without any sign of skin-toxicity even at 200 mg/kg. 
More importantly, it revealed potent efficacy in an ex-vivo model of human skin-infection (with 
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reduction of 85% MRSA burden at 50 μg/mL), which indicates great potential of the compound 
as an antibacterial agent to treat skin-infections. 
KEYWORDS:  Antibiotic-resistance, biofilms, skin-infections, membrane-active agents, 
molecular arrangement
Rampant emergence of antibacterial resistance and antibiotic tolerance due to biofilm formation 
has raised a challenging threat in the face of public health globally.1-4 In this state of alarm, 
development of novel antibacterial molecules capable of displaying antibiofilm property is 
highly necessary. In the recent past, membrane-active molecules, specifically small molecular 
designs, have emerged as possible future antibacterial agents that bear enormous potential to 
solve the antibiotic crisis in the clinic. The design of this class of molecules derives its 
inspiration from naturally occurring antimicrobial peptides (AMPs).5 Unlike the conventional 
antibiotics, AMPs act on bacteria primarily by targeting their membranes, which is advantageous 
because of  slow to no propensity of resistance development.5,6 AMPs are also reported to 
display antibiofilm properties, indicating their potential for developing as modern antibacterial 
agents.7-9 However potent these AMPs as antibacterial agent may be, they suffer from several 
limitations such as complex synthetic design, expensive solid-phase synthesis, low selectivity, 
proteolytic degradation and so on.6 Therefore, a plethora of synthetic mimics of AMPs have been 
developed to address the aforementioned limitations.10-33 Despite the diversity in the structural 
design, the presence of net positive charge is a common feature of this class of molecules, which 
ensures selectivity towards negatively charged bacterial membrane through initial electrostatic 
interaction. Along with positive charge, the role of amphiphilicity has also been explored 
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extensively in designing membrane-active molecules. The concept of facial amphiphilicity in 
designing membrane-active molecules was directly implemented into arylamide foldamers, urea, 
phenylene-ethylene oligomers, etc.16,33 However, later on the concept of facial amphiphilicity 
was found to be very much design specific and is not applicable to all classes of membrane-
active designs. For example, structurally flexible oligo-acyl-lysines that lack facial amphiphilic 
topology also displayed potent antibacterial activity.34 Rather than amphiphilic topology, 
optimum hydrophobic/hydrophilic balance is recognized as a much more applicable concept in 
designing membrane-selective antibacterial molecules. It has even been seen that optimum 
hydrophobic/hydrophilic balance plays the major role over conformational stiffness to control 
antibacterial activity, when both the factors are incorporated in the same design.18 However; the 
aspect of molecular arrangement of hydrophobic and hydrophilic groups could be another 
important concomitant parameter, which remains largely unknown. Here we investigate the role 
of molecular arrangement in a membrane-active design by modulating hydrophobicity between 
charges. The molecular design consists of a symmetric triamine in the backbone, where the 
Figure 1. Chemical structure of small molecular antibacterial agents with hydrophobicity 
modulation between charges.
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cationic amino acid is conjugated with the two terminal amino groups along with an aliphatic 
long chain which is attached with the middle secondary amino group. We have reported that 
molecules with norspermidine (bis(trimethylene)triamine) present in the backbone and consisting 
of various hydrophobic amino acids including lysine have displayed potent antibacterial 
efficacy.22,35,40 Thus, we were interested to further explore this molecular design. In the first 
series of compounds, the modulation of hydrophobicity was achieved through varying 
hydrophobicity between α-amino group and the amino group present in side chain of positively 
charged amino acids (Series 1, Figure 1). In a second series of compounds, the backbone 
hydrophobicity of the design was varied by incorporating a triamine such as diethylene triamine 
and bis(hexamethylene)triamine instead of bis(trimethylene)triamine (Series 2, Figure 1). By 
varying the backbone triamine in the design, we could modulate hydrophobicity between the 
charges of two amino acids placed at either end of the design. In both the series of compounds, 
the aliphatic long chain was varied by incorporation of dodecanoyl, tetradecanoyl and 
hexadecanoyl groups to obtain the optimized compound. Additionally, for the second series of 
compounds, we also prepared octanoyl and decanoyl analogues to better understand the 
structure-activity relationship. The antibacterial activity of the compounds was evaluated against 
both classes of bacteria (Gram-positive and Gram-negative) and the toxicity was tested against 
human red blood cells (hRBCs). The optimized lead compound was then obtained by 
determining the selectivity index (HC50/MIC). The antibacterial efficacy of the lead compound 
was evaluated further by performing additional experiments such as cytotoxicity against 
mammalian cells (HEK cell line), time-kill kinetics, activity against metabolically inactive 
bacteria (such as stationary and persister cells) and membrane-active mode of actions. The 
antibiofilm ability was investigated against established biofilms and resistance development 
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studies were performed to show the long-lasting antibacterial activity of this compound. The in-
vivo antibacterial activity was examined in a mouse model of skin-infection and toxicity was 
evaluated in acute dermal model in mice. Finally, the potency of the compound was evaluated in 
an ex-vivo model of human skin-infection.  
RESULTS AND DISCUSSION
Design and Synthesis: In order to understand how molecular arrangement plays a role in 
dictating selective antibacterial activity, two series of compounds were synthesized by varying 
the positively charged amino acid (Series 1) and the backbone triamine of the design (Series 2). 
An aliphatic long chain in both the series was varied in order to tune the hydrophobicity in the 
molecules. In the first series, a total of nine compounds (1j-1r) were prepared by incorporating 
the amino acids diaminobutyric acid (Dab), ornithine (Orn) and lysine (Lys) with various 
aliphatic long chains (Series 1, Figure 1). In the second series of compounds, which were 
achieved by varying the backbone of the design, the amino acid was kept fixed as lysine (Series 
2, Figure 1). In this series, the compounds (2o-2s) consisted of diethylene triamine in the 
Scheme 1. Synthesis of small molecular antibacterial agents with hydrophobicity modulation 
in amino acid side chain.
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backbone of the molecule, bearing aliphatic long chains varying from octanoyl to hexadecanoyl 
group. Compounds (2t-2y) also possessed varied long chains of octanoyl to hexadecanoyl with 
bis(hexamethylene)triamine present in the backbone of the molecules. All the compounds 
consisted of L-configuration of amino acid except the compound 2y, which bears D-lysine in its 
structure.
Synthesis of the first series of compounds was achieved by two-step reactions starting 
from the precursor amines (Scheme 1). The primary amino groups of the precursor amine were 
first coupled with carboxylic acid groups of Nα-Boc-Nγ-Boc-L-2,4-diaminobutyric acid, Nα-Boc-
Nδ-Boc-L-ornithine or Nα-Boc-Nε-Boc-L-lysine. In the next step, the Boc-groups were removed 
by using TFA (trifluoroacetic acid) to achieve the final compounds. The synthesis of the second 
series of compounds was achieved by three step reactions (Scheme 2). Two primary amino 
groups of the triamine (diethylene triamine or bis(hexamethylene)triamine) were first coupled 
Scheme 2. Synthesis of small molecular antibacterial agents with hydrophobicity modulation 
in the backbone. 
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with carboxylic acid group of Nα-Boc-Nε-Boc-L/D-lysines. In the second step, various aliphatic 
long chains were attached at the centrally placed secondary amino group by performing another 
coupling reaction (Scheme 2). Finally, the Boc groups were removed to achieve the final 
compounds (2o-2y). The details of synthesis, characterization, HPLC trace and HPLC purity 
percentage of the compounds are provided in the experimental section and supporting 
information (Supporting Information Figure S1-S33).
Antibacterial Activity: To investigate the role of molecular arrangement in guiding the 
antibacterial activity, the entire library of compounds was tested against various Gram-positive 
(S. aureus, MRSA) and Gram-negative (E. coli, P. aeruginosa) bacteria. The antibacterial 
activity is expressed in terms of MIC (minimum inhibitory concentration) values (Table 1). 
Effect of Hydrophobicity Modulation in Amino Acid Side Chain. Analysing the antibacterial 
activity for the first series of compounds (1j-1r), where tunable hydrophobicity was borne out of 
the variation of amino acid side chains, suggested that decreasing the distance between charges 
leads to decrease in activity (Table 1). Dab series of compounds (1j-1l) were active with the MIC 
values mostly in the concentration range between 6.3-≥50 µg/mL (except the hexadecanoyl 
analogue, MIC = 3.1-6.3 µg/mL). Orn homologues (1m-1o), with an additional methylene group 
in the side chain showed improvement in their antibacterial profile. The compounds exhibited the 
MIC values in the concentration range of 3.1-25 µg/mL except a value of >50 µg/mL was 
observed against E. coli for dodecanoyl analogue (1m). Unsurprisingly, the Lys bearing 
compounds (1p-1r) that possess the highest hydrophobicity in their side chain showed the best 
antibacterial activity profile in this series. This becomes much clearer when comparing the MIC 
values of the lower long chain containing analogues of this series of compounds. While 
dodecanoyl analogue of Orn and Dab containing compound displayed MIC value of 25->50 
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µg/mL, corresponding Lys containing compounds displayed MIC values at concentration 12.5-
50 µg/mL (except E. coli). Along the same line, the tetradecanoyl analogue of Lys containing 
compound displayed very good activity with the MIC values in the concentration range of 3.1-
6.3 µg/mL, while Orn and Dab bearing analogues showed a concentration range of 3.1-25 
µg/mL. Overall analysis suggested that Dab series of compounds are the least active, whereas 
Lys containing compounds, which possess the highest hydrophobicity in the side chain, are the 
most active. It was noteworthy that the above mentioned principle was not followed by 
Table 1. Antibacterial and hemolytic activities of the compounds.
Minimum Inhibitory Concentration (µg/mL)
Gram-positive Bacteria Gram-negative BacteriaCompounds

















































































































































aSI stands for selectivity index that was determined considering MIC values against MRSA. 
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hexadecanoyl analogue compounds. This probably indicates that beyond an optimum length in 
lipidated chain, the effect of hydrophobicity variation between charges can no longer be seen due 
to greater hydrophobic effects from the long aliphatic chain in the design. 
Effect of Hydrophobicity Modulation in the Backbone. Structure-activity analysis suggested that 
Lys containing compounds are the most active compounds in the series. We therefore moved 
forward with investigating the effect of backbone variation for this amino acid in particular. 
Overall, we saw that antibacterial activity is highly dependent on backbone hydrophobicity in the 
molecules. An improved antibacterial activity was found upon increasing the hydrophobicity in 
backbone from bis(trimethylene)triamine (six methylene groups) to bis(hexamethylene)triamine 
(twelve methylene groups) and it was compromised with decreased hydrophobic backbone of 
diethylene triamine (four methylene groups). The shortest long chain bearing compound 
(octanoyl analogue), 2t, with highest backbone hydrophobicity (bis(hexamethylene)triamine) did 
not display much antibacterial activity. However, a moderate activity was observed for the next 
compound, 2u, in this series that consisted of decanoyl long chain. Further increasing the long 
chain to dodecanoyl group, the resulting compound 2v and its corresponding D-isomeric 
compound 2y displayed excellent antibacterial activity. They were active with MIC values of 
3.1-6.3 µg/mL. In comparison, the dodecanoyl analogue compounds with lesser backbone 
hydrophobicity, such as bis(trimethylene)triamine (1p) and diethylene triamine (2q) exhibited 
very limited antibacterial activity, which highlights the role of backbone hydrophobicity in 
dictating antibacterial activity. This role of backbone hydrophobicity was also reproducible in 
the tetradecanoyl derivatives. The tetradecanoyl compound with diethylene triamine and 
bis(trimethylene)triamine backbone showed MIC values in the concentration range of 6.3-25 
µg/mL and 3.1-6.3 µg/mL respectively, whereas the analogue compound with 
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bis(hexamethylene)triamine backbone displayed the activity with MIC value of 3.1 µg/mL. Like 
the previous case, here too, we observed that the role of backbone hydrophobicity became 
unseen in case of the long lipidated derivatives. Table 1 illustrates that the hexadecanoyl 
analogue compounds of varied hydrophobic backbone 1r, 2s, 2x displayed the MIC value of 3.1 
µg/mL against all the bacteria tested. Collectively the results suggest that hydrophobicity 
between charges indeed plays an important role in membrane active design with shorter lipidated 
chain. However, this appears unseen for the higher lipidated analogues, where increased 
hydrophobic interaction brought about by long lipophilic moiety is guiding the antibacterial 
activity to a greater extent. 
Hemolytic Activity and Selectivity: Preliminary toxicity study was performed by evaluating the 
hemolytic activity of the compounds. In order to quantify the hemolytic activity, the HC50 
(defined as compound concentration corresponding to 50% lysis of the hRBCs) values were 
determined (presented in table 1). 
Effect of Hydrophobicity Modulation in Amino Acid Side Chain. An overall observation 
suggested that hemolytic activity was highly dependent on hydrophobicity variation in the amino 
acid side chain. Analysing the results for the compounds (1j-1r), it was found that dodecanoyl 
analogues of Dab, Orn and Lys bearing compounds were completely non-toxic even at 1000 
µg/mL. However, the effect of side chain hydrophobicity on hemolytic activity was observed for 
tetradecanoyl and hexadecanoyl derivatives. While the tetradecanoyl derivative of Dab and Orn 
containing compounds displayed HC50 values 170 µg/mL and 305 µg/mL, respectively, the Lys 
bearing compound showed a higher value of 561 µg/mL. Similarly, the hexadecanoyl derivative 
of Lys containing compound displayed a higher HC50 value of 133 µg/mL compared to Dab and 
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Orn bearing compounds that showed the values of 60 µg/mL and 70 µg/mL, respectively. Taken 
together the results suggest that the Lys series of compounds which possess higher side chain 
hydrophobicity are the least toxic compared to Dab and Orn bearing compounds that possess 
lesser hydrophobicity in amino acid side chain. This was reflected markedly in the selectivity 
index as determined by the ratio of HC50 and MIC values. The tetradecanoyl derivative of Lys 
consisting compound displayed a selectivity index of 181, whereas the corresponding Orn and 
Dab derivatives showed much lesser values of 48 and 27 respectively (Table 1). Thus, Lys series 
of compounds were highly selective compared to Dab and Orn comprising compounds.     
Effect of Hydrophobicity Modulation in the Backbone. Hemolytic activity was also found to be 
dependent on backbone hydrophobicity. Overall analysis suggested that shorter long chain 
containing compounds (such as octanoyl and decanoyl derivatives) were completely non-toxic 
(HC50 value >1000 µg/mL), whereas hexadecanoyl derivatives, 2s and 2x were relatively toxic 
and displayed HC50 values of 87 and 90 µg/mL, respectively. The dodecanoyl and tetradecanoyl 
derivatives with decreased hydrophobic backbone (diethylene triamine) displayed HC50 values of 
>1000 µg/mL and 765 µg/mL, respectively. In comparison, the tetradecanoyl derivative with 
increased hydrophobic backbone (bis(hexamethylene)triamine), 2w, showed a HC50 value of 253 
µg/mL, and the dodecanoyl analogue compound (2v) displayed a value of 860 µg/mL. Therefore, 
a general analysis suggested that an increase in backbone hydrophobicity resulted in a slight 
increase in hemolytic activity. However, the simultaneous increasing effect on antibacterial 
activity leads to high selectivity index as compared to the analogue compounds with decreased 
backbone hydrophobicity. The dodecanoyl derivative (2v) and its corresponding D-isomeric 
compound, 2y, displayed the highest selectivity index of 277 and 287 respectively, when 
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calculated for MRSA (Table 1). Combined together, the results therefore suggested that an 
increase in hydrophobicity between charges leads to selective antibacterial compounds.  
Cytotoxicity against HEK Cells: To further investigate the selectivity of the lead compound 2y, 
toxicity was determined against HEK cells by both MTT assay and live-dead assay through 
fluorescence microscopy. Both the experiments suggested that the compound was not toxic even 
at a concentration of 40 µg/mL (6-13 folds higher as compared to MIC values). In Figure 2, the 
Figure 2. Fluorescence microscopy images of HEK cells under different conditions. Scale 
bar: 50 µm. 
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live-dead assay suggested that there were no dead cells (corresponding to red fluorescence), in 
complete agreement with the MTT assay which showed 100 % cell viability at this concentration 
(Supporting Information Figure S34a). However, at the next higher concentration of 80 µg/mL, 
the compound displayed slight toxicity. To have a quantitative readout, the EC50 value 
(concentration of the compound at which 50% of the treated cells remain viable) was 
determined.  The EC50 value was found to be 85 µg/mL (Supporting Information Figure S34b), 
which was significantly higher (13-27 fold) compared to the concentration at which it displayed 
antibacterial activity.  
Time-kill Kinetics: The time kill-kinetics of 2y was performed against both Gram-positive (S. 
aureus) and Gram-negative (E. coli) bacteria. Complete killing (>5 log CFU/mL reduction) of S. 
aureus was found within 180 and 360 min at 25 µg/mL and 12.5 µg/mL, respectively 
(Supporting Information Figure 35a). Although the compound displayed comparatively slower 
killing kinetics against E. coli, around 3 log reduction (corresponds to bactericidal activity) in 
cell viability was observed within 360 min of treatment with 50 µg/mL of compound 
(Supporting Information Figure 35b). Taken together, the results illustrated the bactericidal 
nature of the compound against both of the bacteria. Moreover, the faster rate of killing of S. 
aureus than E. coli probably indicated the better interaction of the compound with Gram-positive 
bacteria, which are known to possess a much simpler cell envelope structure compared to Gram-
negative ones.40
Antibacterial Activity against Non-dividing Dormant Bacteria: Although conventional 
antibiotics are capable of killing growing bacterial cells, they remain ineffective against non-
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dividing dormant bacteria. Therefore, new antibacterial agents that would also be active against 
these slow or non-growing bacteria are highly sought after. To this end, we have investigated the 
killing efficacy of optimized compound, 2y, against metabolically inactive stationary and 
persister cells of S. aureus as well as E. coli. The dormant cells were created by following a 
reported protocol and the details are provided in the experimental section.35 At first, the midlog 
phase dividing bacterial cells were allowed to grow to non-dividing stationary phase cells. The 
persister bacterial cells were then prepared from stationary phase culture by treating with 
ampicillin sodium. The efficacy of the test compound was compared with conventional 
antibiotics ampicillin (for both S. aureus and E. coli), vancomycin (for S aureus) and 
Figure 3. Antibacterial efficacy against stationary and persister cells: (a) antibacterial 
activity against S. aureus, (b) antibacterial activity against E. coli. Potency of the compound 
2y was compared with the antibiotics Amp (for both S. aureus and E. coli), Van (for S. 
aureus) and Ery (for E. coli). In the figure Amp, Van and Ery represents Ampicillin, 
Vancomycin and Erythromycin respectively and the symbol asterisks (*) correspond to <50 
CFU/mL.
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erythromycin (for E. coli). The results suggested that the test compound, 2y, was capable of 
killing dormant cells of both S. aureus and E. coli, whereas all the control antibiotics remained 
ineffective against such dormant bacterial cells. This clearly illustrated the effectiveness of this 
new antibacterial compound over conventional antibiotics. Figure 3a demonstrates that 
compound 2y not only reduced bacterial viability (~ 3 log reduction at concentration of 50 
µg/mL), but was also capable of completely killing the stationary (~ 5 log reduction) and 
persister (~ 6 log reduction) S. aureus within 2 h at a concentration of 100 µg/mL. In 
comparison, ampicillin and vancomycin (a last-resort antibiotic against Gram-positive infections) 
remained completely ineffective even at the concentration of 100 µg/mL. Furthermore, 
compound 2y also displayed high efficacy against the stationary and persister cells of E. coli. 
Complete killing of bacterial cells (~ 5 log reductions in stationary and ~ 6 log reductions in 
persister viability) was observed upon treatment with 100 µg/mL of test compound (Figure 3b). 
Here too, the control antibiotics ampicillin and erythromycin remained completely ineffective at 
this concentration. Taken together the results therefore suggested enormous potential of 2y to 
treat metabolically inactive dormant bacteria against which conventional antibiotics fail to show 
any activity.
Membrane Depolarization of Growing Planktonic and Non-dividing Dormant Bacteria: An 
optimum membrane potential is crucial for the functioning of various biological processes in 
bacteria. Therefore, a perturbation in bacterial membrane potential can lead to death of bacterial 
cells. Membrane targeting mode of action against both growing planktonic as well as 
metabolically inactive stationary and persister cells was hence investigated by performing 
membrane depolarization assay. Compound 2y was assayed against all such metabolically 
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distinct cells. The dye DiSC3 (5) was used to monitor the effect of compound on bacterial 
membrane potential. DiSC3 (5) distributes inside bacterial cells based on the normal bacterial 
membrane potential, but any disruption of this normal potential results in release of dye into the 
external medium that leads to an increase in fluorescence intensity.  Our results suggested that 
test compound 2y showed appreciable destabilization in membrane potential irrespective of the 
metabolic state of both S. aureus and E. coli cells (Figure 4 and Supporting Information Figure 
S36). An increase in fluorescence was observed even at a concentration of 6.3 µg/mL, and 
importantly a dose-dependent enhancement in intensity was seen with increase in the compound 
concentration (Figure 4). Furthermore, the propidium iodide (PI) assay revealed that the test 
compound, 2y, does not show a significant membrane permeabilization effect (Figure S37). 
Taken together, the results therefore suggested that this class of compounds act on metabolically 
distinct bacterial cells primarily by destabilizing their membrane potential.
Resistance Studies: In this current state of affairs where there is a rapid emergence of antibiotic 
resistance, it is imperative to develop new antibacterial agents possessing long-lasting efficacy. 
Therefore, propensity of resistance development against 2y was investigated for both S. aureus 
Figure 4. Membrane depolarization of metabolically distinct S. aureus cells; (a) Growing 
planktonic cells, (b) Stationary phase cells, (c) Persister cells. Studies were performed by 
using the membrane potential sensitive dye DiSC3 (5) and the arrow in the figures 
corresponds to addition of compound. 
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(Gram-positive representative) as well as E. coli (Gram-negative representative). Results clearly 
suggested that bacteria were unable to develop resistance against this new compound even after 
14 subsequent passages. The MIC values of the test compound remained almost unchanged over 
the experimental time span (Supporting Information Figure S38). On the contrary, S. aureus and 
E. coli were observed to develop high level of resistance against the antibiotics norfloxacin and 
colistin, respectively.22,35 Taken together, these results firmly suggested that both classes of 
bacteria find difficulties in developing resistance against this new compound, thereby 
highlighting the long-lasting antibacterial efficacy over conventional antibiotics.
Anti-biofilm Activity: Biofilm associated infection is one of the major threats faced by public 
health today. According to the current scenario, 70-80% of infections are in association with 
biofilm formation, and are usually difficult to treat with conventional antibiotic therapy.36 MRSA 
is one such dangerous bacterium, which shows a high propensity for biofilm formation. A major 
percentage of community as well as hospital acquired infections are caused by MRSA.37,38 The 
World Health Organization (WHO) has unsurprisingly categorised MRSA as one of the critical 
bacteria, against which new antibacterial agents need to be developed urgently.39 Hence, we 
investigated the efficacy of the optimized compound 2y as an anti-biofilm agent to tackle MRSA 
infections. The biofilm disruption ability of the compound was measured by crystal-violet (CV) 
staining and the efficacy was compared with the anti-MRSA antibiotics fusidic acid and 
vancomycin (a last resort antibiotic for MRSA). The results suggested that the compound 2y 
could eradicate a significant amount of the established biofilm, whereas fusidic acid and  
vancomycin hardly displayed any efficacy (Figure 5a). Compound 2y displayed about 40% and 
80% reduction in biofilm biomass at 20µg/mL and 40µg/mL respectively, whereas control 
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antibiotics showed around 10-20% reduction at 40µg/mL. Further, the extent of biofilm 
disruption was visualized through confocal laser scanning microscopy (CLSM), where the 
biofilms were stained with the dye Syto-9, a fluorescent nucleic acid stain. Compared to the 
untreated control, the compound treated sample possesses lesser green fluorescence, which 
confirmed that the compound has significant biofilm eradication ability.  
In-vivo Efficacy in Mice Model: In order to evaluate the efficacy of 2y as a topical antibacterial 
agent, toxicity was evaluated in mice by performing acute dermal toxicity studies. A dose of 200 
mg/kg was used for this study. After exposure of the test compound, the treated mice group was 
kept under careful observation for 14 consecutive days. It was found that the compound did not 
induce any kind of adverse effects such as irritation, tremors, convulsions, salivation and so
Figure 5. (a) Quantification of biofilms disruption through CV staining. In figure Van and Fus 
represent the antibiotics Vancomycin and Fusidic acid, respectively, (b) Confocal laser 
scanning microscopy (CLSM) images of MRSA biofilms after staining with SYTO-9. The 
scale bar is 10 μm in the figure. 
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on. Additionally, normal fur growth was observed, similar to untreated group of mice further 
indicating nontoxic nature of the compound (Figure 6a). Thus, the results suggest that this 
compound has potential for development  as an agent for treatment of topical infections.
The in-vivo activity of 2y was then evaluated in a mouse model of MRSA skin infection. 
Two groups of infected mice received either 20 mg/kg or 40 mg/kg of the compound treatment 
(40 µL, applied topically), whereas saline was administered to the control group of mice. After 
four days of continuous treatment (four doses: 24 h interval), the lead compound reduced 
bacterial burden by 2.8 log and 3.9 log at 20 mg/kg and 40 mg/kg, respectively (Figure 6b). 
Encouragingly, the test compound not only demonstrated activity under in-vitro scenario, but 
was also found to show excellent in-vivo activity. These results suggest that compound 2y shows 
significant promise as an agent for treating MRSA skin-infections.
Figure 6. (a) Photographic images of the mice after 14 days of compound exposure. Blue 
circle indicated normal fur growth in mice for both untreated as well as compound treated 
case, (b) Bacterial titer in mice model of superficial skin-infection. 
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Toxicity in Ex-vivo Model of Human Skin: To elucidate the real possibility of using compound 
2y as a topical antibacterial agent, efficacy was tested in human skin. The toxicity of compound 
was first evaluated towards human skin ex-vivo. At first, models of human skin was engineered 
ex-vivo by following established protocol.43  The models were cut into 4 equal pieces and then 
fully submerged in presence of compound 2y for 24 h at concentrations from 20 μg/mL  to 5000 
µg/mL. Treatment with compound 2y revealed a dose-dependent toxicity response (Figure 7). 
Concentrations of up to 100 µg/mL did not cause any significant damage or reduce the tissue 
viability, as quantified by alamar blue assay. Concentrations between 20-100 µg/mL were 
therefore selected for testing against MRSA-infected ex-vivo skin.
 
Figure 7. Toxicity of compound 2y in ex-vivo model of human skin after 24 h exposure. (a) 
Photographic images showing skin post-staining with alamar blue. Blue, dead tissue or 
decellularised dermis. Pink, viable tissue. (b) Quantification of skin viability, where data is 
expressed as % viability to untreated control (0 µg/ml). n=3. One-way ANOVA (vs. untreated 
control). 
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Antibacterial Activity in Ex-vivo Model of Human Skin Infection: Antibacterial activity of 
compound 2y was evaluated in ex-vivo model of MRSA-infected human skin at non-toxic 
concentrations of ≤100 µg/mL. Skin was treated with single or multiple doses (up to 3) of 
compound 2y or vancomycin at 24 h intervals (Figure 8a-c). Although, vancomycin was found to 
be highly effective at higher concentration such as 8 µg/mL and 16 µg/mL (Figure 8a), no 
significant activity was observed at 4 μg/mL, regardless of the number of doses/length of 
treatment. Our test compound, 2y, also revealed significant efficacy, with a single dose of 100 
µg/mL showing comparable reduction to vancomycin at 8 µg/mL. Treatment with compound 2y 
demonstrated a dose-dependent reduction in bacterial infection (Figure 8a). After 3 doses, the 
compound was able to reduce bacterial infection by 85% at 50 µg/mL (Figure 8c). Taken 
together the results therefore indicated real possibility of this newly developed compound to be 
developed as antibacterial agent to treat skin infections.
Figure 8. Antibacterial activity of 2y in ex-vivo model of human skin infection. MRSA-
infected skin was treated with 1 dose (a), 2 doses (b), or 3 doses (c) of 2y (MIC = 12.4 μg/mL) 
or Van (vancomycin, MIC = 0.8 μg/mL) at 24 h intervals. Data (CFU per mg skin) is expressed 
as % bacterial infection to untreated control, n = 3, one-way ANOVA (vs. control). 
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To summarize, a series of small molecules were developed by varying spatial distribution of 
hydrophobic groups in a membrane-active design. Antibacterial and toxicity studies revealed that 
some of the compounds were selective towards bacterial killing over mammalian cells, with 
insights into the role of molecular arrangement of hydrophobicity. This finding highlighting the 
role of molecular arrangement of hydrophobicity will have significant insight to design non-toxic 
membrane-active molecules with high antibacterial potency. The lead compound was rapidly 
bactericidal against growing planktonic bacteria and also completely eradicates their stationary 
and persister cells. The compound also displayed potent antibiofilm activity and bacteria were 
unable to develop resistance against this compound even after 14 continuous passages. More 
importantly, it displayed in-vivo activity with significant reduction of bacterial burden without 
any sign of toxicity in mice and revealed good antibacterial efficacy in ex-vivo model of human 
skin-infections. Thus, the lead molecule bears potential to be developed as an antibacterial agent 
to treat skin infections. 
EXPERIMENTAL SECTION
Antibacterial Assay: The assay was performed by following our reported protocol.40-42 Detailed 
experimental protocol is provided in supporting information. 
Hemolytic Assay: The details of experiment is provided in supporting information. 
Toxicity study against HEK cells: 
Live-dead assay and cell morphology analysis through bright filed images.42 Briefly, human 
embryo kidney (HEK 293) cells were seeded into 96-well plate in complete DMEM media 
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(supplemented with 10% fetal bovine serum and 5% penicillin-streptomycin) and grown to 70-
80% confluency. After that, the cells were treated with 40 μg/mL and 80 μg/mL of compound 
2y. Two control experiments were also performed, while in one case cells were treated with 
media containing no compound (untreated) and for the other case cells were treated with 0.1 vol 
% Triton X-100 solution. The plate was then incubated for 24 h at 37 ºC under 5% CO2 
atmosphere. At the end, the media was discarded and cells were washed once with 1X PBS and 
stained with calcein AM (2 μM, Fluka) and propidium iodide (PI, 4.5 μM) (Sigma-Aldrich) for 
15 min. After that, the dye containing solution was discarded and the cells were washed with 1X 
PBS to remove the excess dyes. The images of the cells were then captured with a 40X objective 
in a Leica DM2500 fluorescence microscope. A band-pass filter for calcein AM at 500-550 nm 
and a long-pass filter for PI at 590-800 nm were used while imaging. For bright field images 
another experiment was performed by following the same protocol as mentioned above, where 
the images of the cells directly were captured after 24 h of compound treatment instead of 
staining with dyes. 
MTT assay. The experiment was performed by following established protocol with slight 
modification.40 Briefly, the HEK cells seeded into 96-well plate in complete DMEM media 
(supplemented with 10% fetal bovine serum and 5% penicillin-streptomycin) and grown to 70-
80% confluency. After that the medium was diacarded and various concentration of test 
compound 2y diluted in DMEM media was added to the cells. Both the negative and positive 
controls were included in the experiment. As the negative control, same volume of media was 
added and for the positive control 0.1 vol % of Triton X-100 was added instead of compound. 
The treated plate was then incubated for 24 h at 37 °C under 5% CO2 atmosphere. At the end, the 
10 μL of MTT solution (5 mg/mL concentration) was added to wells and incubated for another 4 
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h. After that, it was centrifuged at 1100 rpm for 5 min and the supernatant was discarded and 
washed with 1X PBS. 100 μL of DMSO was then added to solubilize formazan crystals formed 
due to reduction of MTT. Finally, the optical density (OD) of the plate was then recorded at 570 
nm and the percentage of cell viability was calculated using the following equation: Cell 
viability (%) = (At-ATXt)/(Ant-ATXt)×100; where At corresponds to OD of treated sample, Ant for 
non-treated negative control and ATXt OD of Triton X-100 treated positive control. Each 
concentration had triplicate values and the average data was plotted against concentration 
followed by fitted with sigmoidal plot. From the curve the concentration corresponds to 50% cell 
viability was determined to be EC50 value. 
Time-Kill Kinetics: Time kill kinetics of optimized compound 2y was investigated against both 
S. aureus as well as E. coli. Briefly, the test compound of required concentartion was prepared in 
autoclaved milipore water and 50 µL was added to the wells of 96-well plate. Then, 6 h grown 
mid-log phase bacterial culture was diluted to ~106 CFU/mL in nutrient broth and 150 µL of 
these suspension were added to the compound containing wells. In case of control experiment 
same volume of autoclaved milipore water was added instead of compound solution. After that, 
20 µL of aliquots from that solution were 10-fold serially diluted in 0.9 % saline at different time 
intervals (0, 30, 60, 180 and 360 min). 20 µL of these serially diluted dilutions were then spot 
plated on agar plates and incubated for 24 h at 37 ºC. Colonies were then counted and bacterial 
cell viability was presented in logarithmic scale. 
Antibacterial activity against dormant bacterial cells:  Preparation of stationary and persister 
cells was achieved by established protocol.35 Briefly, 6 h grown midlog phase culture of S. 
aureus and E. coli were diluted to 1:1000 in nutrient and LB broth and allowed to grow for 16 h 
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to atain the stationary phase. To prepare persister cells, stationary phase culture was treated with 
ampicillin sodium (100 µg/mL for S. aureus and 300 µg/mL for E. coli) of for 3h at 37 °C. These 
stationary and persister bacterial culture  were centrifused at 9000 rpm for 2 min, and washed 
with  MEM (S. aureus) or M9 media (E. coli). It was then resuspended and diluted to ~105-6   
CFU/mL in MEM (S. aureus) or M9 media (E. coli). 150 µL of these bacterial suspension were 
then added to the 96-well plate containing 50 µL of test compound 2y and control antibiotics in 
respective medium. In case of the control experiment, same volume of respective media was 
added instead of any antibacterial agents. The plate was then incubated at 37 ºC for 2 h under 
shaking. At the end, the bacterial suspension was serially diluted as 10-fold in saline and 20 µL 
of the diluted solutions were spot-plated on agar plates and incubated for 48 h at 37 ºC. Finally, 
to determine cell viability bacterial colonies were counted and result was represented as Log 
CFU/mL.
Membrane depolarization and permeabilization assay: Reported experimental protocol was 
followed with little modification.41 Detailes are provided in the supporting information.
Resistance studies: Resistance study was performed by following reported experimental 
protocol.35 At first, the MIC values of 2y was determined against both the S. aureus and E. coli 
by following the experimental protocol as described in antibacterial assay. For the next day, the 
second MIC experiment was performed for the compound where the bacterial suspension was 
prepared from the grown bacteria at sub-MIC (MIC/2) concentration of first MIC experiment. 
Next day then third MIC experiment was performed same as the previous experiment by taking 
bacterial suspension from sub-MIC concentration of second MIC experiment. This process was 
repeated for total of 14 contineous day. At the end of the experiment, the fold of increase in MIC 
values were then determined and plotted it against the number of days.
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Quantification and visualization of biofilm disruption: At first, MRSA biofilms were grown 
on glass coverslip by following reported protocol.41 Briefly, midlog phase MRSA culture (~108 
CFU/mL) was diluted to ~105 CFU/mL in nutrient broth supplemented with 1% glucose and 1% 
NaCl.  2 mL of the bacterial suspension was then added into 6 well plate containing a sterile 18 
mm of sterile glass coverslip. Biofilm was the allowed to grow on coverslip for 24 h under 
stationary condition at 37 ºC. After that, the coverslips consisting of biofilms were carefully 
washed with 1X PBS and placed into the wells of the 6-well plate containing 2 mL of the various 
concentration of 2y and control antibiotics (diluted in the complete biofilm media). In case of 
untreated control experiment the same volume of respective medium was added instead of any 
antibacterial agents. The plate was incubated at 37 ºC for 24 h under stationary condition. At the 
end, the coverslips were washed with 1X PBS and placed into wells of another 6-well plate and 
allowed to dry. After that, the disrupted biofilms contained coverslips were stained with crystal-
violet (2 mL of 0.1% w/v solution prepared in sterile milipore water) for 5-10 min. The stained 
biofilms were washed with 1X PBS and placed into the wells of another 6-well plate and 2 mL 
of 95% ethanol in water was added to solubilize the stained CV. Finally, the OD of the solution 
at 520 nm was recorded by using plate reader and percentage of biofilm biomass was calculated 
by considering 100 percentage for untreated control. To visualize the extent of biofilm disruption 
by the test compound 2y, experiment was performed by following the same protocol. Here the 
only difference was that the disrupted biofilms were stained with the dye syto-9 instead of 
crystal-violet and images were captured by using confocal laser scanning microscopy.
Acute dermal toxicity:41 In-vivo toxicity was evaluated by performing acute dermal toxicity 
experiment. Briefly, female BALB/c mice (6-8 weeks-old) of body weight 18-22g were 
randomly divided in two groups having five mice in each. The mice were anesthetized with 
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intraperitoneal injection of 150 µL of xylazine-ketamine cocktail. In the anesthetic condition, the 
fur from the back of the mice (~1/10th of total body surface) was removed without any injury on 
the skin. After 24 h, the compound 2y (200 mg/kg) was applied in the shaved area on skin of one 
group of mice. The remaining group was left untreated as the control experiment.  The treated 
group mice were kept under continuous observation for 2 h to monitor if compound exposure 
results any abnormal behavior of mice. After that, both treated as well as untreated group of mice 
were kept under observed for a period of 14 days with specific attention towards furs regrowth in 
the shaved area. 
In-vivo activity in mice model of MRSA skin-infections:  In-vivo anti-MRSA activity of 
compound 2y was evaluated by following a reported experimental protocol.41 Briefly, BALB/c 
mice (female, 6-8 weeks-old) in the range of 18-22 g of body weight were randomly divided in 4 
groups with five mice in each. Mice were then rendered neutropenic by intraperitoneally 
injection of two doses of cyclophosphamide, the doses of 150 mg/kg and 100 mg/kg were 
administrated four days and one day before the experiment. The mice were then anesthetized by 
intraperitoneal injection of 150 µL of xylazine-ketamine cocktail solution. In the anesthetized 
condition, the fur on the back of the mice was removed by using a trimmer followed by they 
were shaving using a razor. Mice were shaved such that a wound could be created, which was 
clearly observed as ruptured and damaged area on the skin. The mice were then infected at the 
wound by placing 20 µL of freshly prepared MRSA suspension in sterile saline (~107 CFU of 
bacteria per mice). The infected mice were then left untreated for 24 h to allow MRSA biofilm 
formation on mice skin. The bacteria in the biofilm of infection site was quantifyed by 
sacrificing one group of mice. The tissue sample at the infection site was collected in 10 mL of 
sterile saline and homogenized. The suspension was then serially diluted by 10-fold in sterile 
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saline. After that, each dilution was spot plated on agar plate and incubated at 37 °C. At the end 
of 24 h, bacterial colonies were counted and results were expressed as log CFU/g of weight of 
the tissue collected from mice. However, the two groups of mice out of three were treated with 
either 20 mg/kg or 40 mg/kg of compound 2y (40 µL, applied topically) and the remaining group 
was treated with same volume of saline. All the groups of mice were treated with 4 doses of 
compounds or saline at 24 h interval. 24 h after the last dose (at day 5) all the mice were 
sacrificed and tissue sample was collected and bacterial cell viability was determined as 
mentioned for the pre-treatment sample.
Ethics statement for ex-vivo studies: All work using human keratinocytes and fibroblasts was 
performed on samples from abdominoplasty or breast reduction surgeries. Participants provided 
written informed consent to donate the skin, which was stored in the patient’s clinical notes. The 
protocol and consent form were approved by the Sheffield NHS Trust, ethics committee 
(reference number 15/YH/0177). Tissues and cells were stored for a maximum of 1 week, and 
used on an anonymous basis. 
Generation of ex-vivo skin models: Skin constructs were produced as previously described.43 
Briefly, human dermal fibroblasts and keratinocytes were isolated from split-thickness skin 
biopsies. Sterile de-epidermised dermis (DED), measuring 2 cm2, was used as a scaffold. DED 
was placed in tissue culture wells and a sterile steel ring (with a diameter of 27 mm) was placed 
on top. Gentle pressure was then applied to obtain a seal. Green’s media was added to cover the 
dermis around, but not submerge, the ring.  Keratinocytes (between P1-P2) and fibroblasts 
(between P5-P8) were seeded in the centre of the ring at a density of 300,000 and 100,000 cells 
per model, respectively. Models were incubated for 2 days as a submerged culture. Models were 
then cultured at an air-liquid interface for 14-18 days. Media was replaced every 2-3 days. 
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Toxicity in ex-vivo skin models: Each human skin model was cut into 4 pieces measuring 
~1cm2 and washed once with PBS. Skin was then transferred to a 24-well plate and exposed to 
compound, 2y, at a concentration of 0 to 5 mg/mL for 24h. After incubation, skin was washed 
twice with PBS and stained with 50 µg/mL Alamar blue for 3h. Aliquots from each well were 
transferred to a black opaque 96-well plate. Fluorescence was measured at excitation 530nm and 
emission 590nm. 
Ex vivo activity in human skin models: Antimicrobial activity of compound, 2y, was assessed 
in the skin models using established protocols.43 Briefly, human skin models were cut into 4 
pieces measuring ~1cm2. Skin was wounded by burning with a soldering iron at 150ºC for 2 
seconds. Skin was then infected with 1x107 mid-log phase MRSA (clinical skin isolate obtained 
from Sheffield Northern General Hospital) for 5h. Infected skin was then washed in PBS and 
incubated for a further 18h in the presence of compound (2y) at concentration of 0-100 µg/mL or 
vancomycin at 5x-40x MIC (Observed MIC: 0.8µg/mL). After incubation, skin was washed, 
weighed, cut into 16 pieces, lysed in 10% saponin and the number of CFU was determined. For 
multiple dose studies, infected skin was treated with 3 doses of compound 2y (50 µg/mL), 
vancomycin (5xMIC) or media only at 24h intervals. Finally, 24h after the last dose (day 4 of 
infection), skin was processed as detailed previously.  
ASSOCIATED CONTENT
Supporting Information. Details of synthesis and characterization of the compounds, spectral 
data, HPLC trace of the compounds, table corresponding to HPLC purity, molecular weight, 
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retention time, figures for cytotoxicity assay, time-kill kinetics and resistance studies. This 
material is available free of charge via the Internet at http://pubs.acs.org.
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